Featured Study Opportunities
The Crohn's & Colitis Foundation utilizes Featured Study Opportunities to collaborate with academic and industry researchers to help enroll patients with Crohn’s disease and ulcerative colitis into clinical studies. The list below highlights our partners' current research studies. Please note that these partners have paid to have their trials posted below. Some partners' studies listed may be recipients of partial or full funding from the Crohn's & Colitis Foundation. This support does not imply recommendation or favor of the Foundation, as the Crohn's & Colitis Foundation does not endorse any particular study.
For a comprehensive listing of all research studies currently recruiting, please click here.
(For e.g NY instead of New York)
Current Results: 68 entries
The purpose of this research study is to help us understand whether a diet can help children with Ulcerative Colitis (UC) to feel better without needing to take additional medications. Currently, it is thought that UC causes an imbalance in the good and bad bacteria that live inside our gut. We also know that certain foods can change how these good and bad bacteria live, and possibly contribute to UC symptoms. We think a specific diet could help create a better balance in your gut and help you feel better. This study is trying to figure out if a diet can help treat UC.
Full Study Title: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study, With a Vedolizumab IV Reference Arm, to Evaluate the Efficacy and Safety of Vedolizumab Subcutaneous as Maintenance Therapy in Patients With Moderately to Severely Active Ulcerative Colitis Who Achieved Clinical Response Following Open-Label Vedolizumab Intravenous Therapy. (3027)
The purpose of this study is to assess the effect of vedolizumab subcutaneous (vedolizumab SC) maintenance treatment in participants with moderately to severely active ulcerative colitis (UC) who achieved clinical response following administration of vedolizumab intravenous (vedolizumab IV) induction therapy.
The main objective of this study is to evaluate the health of the bowel at Week 26 after taking vedolizumab using ileocolonoscopy.
The primary objective of this study is to test the hypothesis that treatment with LY3074828 is superior to placebo in inducing clinical remission at Week 12 in subjects with moderate to severe ulcerative colitis (UC). The secondary objectives are: -To evaluate the safety and tolerability of treatment with LY3074828. -To evaluate the efficacy of treatment with LY3074828 in inducing a clinical response at Week 12. -To evaluate endoscopic remission at Week 12 and Week 52. -To evaluate the effect of maintenance treatment with LY3074828 on the durability of clinical remission, endoscopic remission, and clinical response at Week 52. -To evaluate the effect of LY3074828 on health outcomes/quality of life measures. -To characterize the pharmacokinetic (PK) profile of LY3074828.
Full Study Title: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Vedolizumab Subcutaneous as Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease Who Achieved Clinical Response Following Open-Label Vedolizumab Intravenous Therapy (Study 3031)
The Primary Objective is to assess the effect of vedolizumab SC maintenance treatment on clinical remission at Week 52 in patients with moderately to severely active CD who achieved clinical response at Week 6 following administration of vedolizumab IV at Weeks 0 and 2.
Full Study Title: An Open-Label, 2-Part, Multicenter, Post-marketing Study to Evaluate the Effect of Moderately or Severely Active Ulcerative Colitis or Crohn's Disease on Cytochrome P-450 Enzyme Substrates Compared to Healthy Subjects and the Effect of Vedolizumab Treatment on Cytochrome P-450 Enzyme Substrates in Subjects With Ulcerative Colitis or Crohn's Disease.
This study is designed to find out if having the medical conditions Ulcerative Colitis or Crohn’s Disease affects the way commonly used medications are broken down in the body.
Microbes that live inside the human body provide a wide range of functions that the human body lacks. However, they are also linked to diseases, such as Crohn's disease and ulcerative colitis (collectively called inflammatory bowel disease, or IBD). Recently, it has been shown that newborns carry bacteria transferred from their mothers. We would like to determine how and when maternal bacteria are transferred to a baby from mothers with and without IBD. This information can help us develop novel strategies to limit risk transmission from a mother to a baby.
The primary objective of this study is to observe the long-term safety of Filgotinib in adults who have completed or met protocol specified efficacy discontinuation criteria in a prior Gilead-sponsored Filgotinib treatment study in Crohn's disease (CD).
The Featured Study Opportunities page is made possible in part by: